“Real-World Effectiveness and Safety of Nemolizumab in Moderate-to-Severe Atopic Dermatitis: A Phase IV, Prospective, Non-Interventional Study Design From RE-UNITE-AD (NCT06988605)”. SKIN The Journal of Cutaneous Medicine 10, no. 2 (March 10, 2026): s746. Accessed April 29, 2026. https://skin.dermsquared.com/skin/article/view/4116.